First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of
hematological malignancies and solid tumors. In the dose of escalation part it is to
characterize the overall safety and tolerability profile and determine the recommended
dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary
information about anti-cancer activity will be further explored in the expansion part of the
study.